Amalgent Therapeutics

Amalgent Therapeutics is a private, clinical-stage company founded in 2020 to address the global challenge of severe pain and the safety limitations of current medications. Its innovative approach centers on developing novel combination therapies from existing drugs, aiming to dramatically improve the therapeutic window and safety profile of pain management. Operating from Cambridge, MA, the company is positioned in the high-need but risky space of non-opioid pain therapeutics, with a pipeline of oral candidates intended for the US market.

A platform focused on repurposing and rationally combining existing approved drugs into novel, fixed-dose oral formulations aimed at significantly improving the safety profile of pain therapeutics.

Amalgent competes in the broad pain management space against large pharma companies with opioid and NSAID products, as well as numerous biotechs developing novel non-opioid targets (e.g., NaV1.7, NGF). Its direct competitors are other firms pursuing drug repurposing or combination strategies for pain, where differentiation relies on specific clinical data and IP.